Recombinant Human ULBP2 protein (His Tag)

Species

Human

Purity

>95 %, SDS-PAGE

Tag

His Tag

Activity

EC50: 18-72 ng/mL

Cat no : Eg0858



Product Information

Purity >95 %, SDS-PAGE
Endotoxin <0.1 EU/μg protein, LAL method
Activity
Immobilized Human ULBP2(His tag) at 2 μg/mL (100 μL/well) can bind Human NKG2D (hFc tag) with a linear range of 18-72 ng/mL.
Expression HEK293-derived Human ULBP2 protein Gly26-Ser217 (Accession# Q9BZM5) with a His tag at the C-terminus.
GeneID 80328
Accession Q9BZM5
PredictedSize 22.5 kDa
SDS-PAGE 26-32 kDa, reducing (R) conditions
Formulation Lyophilized from 0.22 μm filtered solution in PBS, pH 7.4. Normally 5% trehalose and 5% mannitol are added as protectants before lyophilization.
Reconstitution Briefly centrifuge the tube before opening. Reconstitute at 0.1-0.5 mg/mL in sterile water.
Storage Conditions
It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
  • Until expiry date, -20℃ to -80℃ as lyophilized proteins.
  • 3 months, -20℃ to -80℃ under sterile conditions after reconstitution.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the recommended temperature.

Background

NKG2D is an activating cell surface receptor that is predominantly expressed on cytotoxic immune cells. NKG2D recognizes a wide range of ligands. In humans, the NKG2D ligand (NKG2DL) includes MICA, MICB, and six members of the ULBP family (ULBP1-6). ULBPs are MHC class I-related molecules. ULBP2 contains two Ig-like domains, the alpha-1 and alpha-2 domains characteristic of the MHC class I family, but lacks the alpha-3 domain. It can be expressed as either a transmembrane or GPI-linked protein, or released from the cell surface. ULBP2 binds and activates the NKG2D, mediating the recruitment and activation of NK cells.

References:

1.D Cosman, et al. (2001) Immunity. 14(2):123-33. 2.Lola Fernández-Messina, et al. (2011). J Cell Sci. 124(Pt 3):321-7. 3.Ruipeng Wang, et al. (2014). PLoS One. 9(3):e91133. 4.Felix M Wensveen, et al. (20118) Front Immunol. 8:9:441. 5.Shixin Duan, et al. (2019) Mol Cancer. 18(1):29.